VivoSim Labs (VIVS) Gains from Investment Securities (2012 - 2017)
VivoSim Labs (VIVS) posted quarterly Gains from Investment Securities of -$8000.0 for Q1 2017, up 20.0% year-over-year from -$6666.7 in Q1 2016, and down 700.0% quarter-over-quarter from -$1000.0 in Q4 2016.
VivoSim Labs (VIVS) Gains from Investment Securities (2012 - 2017) Analysis & Trends
VivoSim Labs' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$8000.0 for Q1 2017.
- In Q1 2017, Gains from Investment Securities rose 20.0% year-over-year to -$8000.0; the TTM figure through Dec 2017 stood at -$8000.0 (down 33.33% YoY), while the FY2017 annual figure was -$4000.0, down 123.53% from the prior year.
- Gains from Investment Securities for Q1 2017 stood at -$8000.0, down from -$1000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $4.8 million in Q3 2013, with the low at -$94000.0 in Q3 2014.
- The 5-year median for Gains from Investment Securities is $2000.0 (2016), against an average of $401916.7.
- Peak annual rise in Gains from Investment Securities reached 90.43% in 2015, while the deepest fall reached 105.0% in 2015.
- VivoSim Labs' Gains from Investment Securities stood at $4.8 million in 2013, then slumped by 99.17% to $40000.0 in 2014, then plunged by 105.0% to -$2000.0 in 2015, then jumped by 50.0% to -$1000.0 in 2016, then tumbled by 700.0% to -$8000.0 in 2017.
- Business Quant data shows VIVS's Gains from Investment Securities at -$8000.0 in Q1 2017, -$1000.0 in Q4 2016, and $5000.0 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -8,000.00 |
| Mar 31, 2017 | -8,000.00 |
| Dec 31, 2016 | -1,000.00 |
| Dec 31, 2016 | -1,000.00 |
| Jun 30, 2016 | 5,000.00 |
| Jun 30, 2016 | 5,000.00 |
| Mar 31, 2016 | -10,000.00 |
| Mar 31, 2016 | -10,000.00 |
| Dec 31, 2015 | -2,000.00 |
| Dec 31, 2015 | -2,000.00 |
| Sep 30, 2015 | -9,000.00 |
| Sep 30, 2015 | -9,000.00 |
| Jun 30, 2015 | 38,000.00 |
| Jun 30, 2015 | 38,000.00 |
| Dec 31, 2014 | 40,000.00 |
| Dec 31, 2014 | 40,000.00 |
| Sep 30, 2014 | -94,000.00 |
| Sep 30, 2014 | -94,000.00 |
| Jun 30, 2014 | 30,000.00 |
| Jun 30, 2014 | 30,000.00 |